Phase 2 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were 18 years of age or older when they entered the previous related study, and who completed the full required treatment period with PF-07868469 along with all assessments at the end of that study.
- People who are willing and able to attend all scheduled visits, follow the treatment plan, complete lab tests, follow lifestyle requirements, and take part in all other study procedures.
- People whose pulmonary arterial hypertension (a serious lung condition) did not get worse or require a hospital stay during the qualifying study.
Who may not be able to join:
- People who are on a waiting list for a transplant (a surgery to replace a tissue or organ) or who have a planned surgery related to their lung condition.
- People who have an ongoing serious health problem that, in the study doctor's judgment, would make participation unsuitable (confirm with trial site).
- People who have ever had hepato-pulmonary syndrome, which is a lung problem linked to liver disease.
- People who are currently prescribed or taking a type of medication known as a GLP-1 agonist.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs); Number of Participants With Change From Baseline in Laboratory Tests Results; Number of Participants With Vital Sign Abnormalities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.